Medicine
Volume 36, Issue 12 , Pages 630-635, December 2008

Parkinson’s disease

Neil Archibald MA BMBCh MRCP is a Clinical Research Fellow at the Institute for Ageing and Health and a Specialist Registrar in Neurology at Newcastle General Hospital, Newcastle-upon-Tyne, UK. His research interests include the non-motor complications of Parkinson's disease in general and visual symptoms specifically. Competing interests: none declared

David Burn FRCP MD MA MBBS is Professor of Movement Disorder Neurology at the Institute for Ageing and Health, Newcastle University and Honorary Consultant Neurologist, Newcastle upon Tyne Foundation NHS Trust, UK. He is also Director of the Clinical Ageing Research Unit on the Campus for Ageing and Vitality. He qualified from Oxford University and trained in general medicine and neurology in Newcastle upon Tyne and London, UK. His research interests include dementia and depression associated with Parkinson's disease and also progressive supranuclear palsy. Competing interests: none declared

Abstract 

Parkinson’s disease (PD) is the second most common neurodegenerative condition affecting patients in the UK after Alzheimer’s disease. It is broadly classified as a ‘movement disorder’ with a variety of clinical features, including bradykinesia, rigidity and tremor. Traditional focus has fallen on the treatment of ‘motor’ complications such as tremor and mobility problems although these features are only a small part of the clinical phenotype. In reality, PD is better defined as a multisystem neurodegenerative disorder causing a large number of motor and non-motor complications, and both aspects will be covered in this update. Diagnosis remains largely clinical and there are many potential pitfalls for the unwary clinician. Successful treatment relies heavily on a multidisciplinary approach with introduction of pharmacological therapy in a gradual, incremental and monitored setting. In the absence of disease-modifying agents, therapy remains symptomatic and complications increase as time progresses. Many of the most disabling complications are non-motor, and management of advanced PD is both complex and challenging.

Keywords: basal ganglia, bradykinesia, dementia, dopamine, dyskinesia, extrapyramidal, non-motor symptoms, Parkinson’s disease, tremor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1357-3039(08)00262-4

doi:10.1016/j.mpmed.2008.09.004

Medicine
Volume 36, Issue 12 , Pages 630-635, December 2008